Drug Profile
Glycopyrrolate/indacaterol/mometasone - Novartis
Alternative Names: Enerzair; Enerzair Breezhaler; ICS/LABA/LAMA inhaled triple therapy - Novartis; IND/GLY/MF; Indacaterol acetate, glycopyrronium bromide and mometasone furoate - Novartis; QVM 149Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Sosei Heptares; Vectura
- Developer Novartis
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Corticosteroids; Glucocorticoids; Indans; Pregnadienediols; Pyrrolidines; Quaternary ammonium compounds; Quinolones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma
Most Recent Events
- 31 Mar 2024 Sosei Heptares is now called Nxera Pharma
- 20 Mar 2023 Novartis Pharmaceuticals plans a phase III trial for Asthma (In children, In adolescents, Treatment-experienced) in (Inhalation) in June 2022 (NCT05776927)
- 29 Dec 2022 University Medical Center Groningen and Novartis completes a phase III trial in Asthma in Netherlands (NCT04259164)